Our initial focus will be in the swine influenza virus (SIV) market. We plan to develop our HISP-P™ and HeptaVac™ products to fill an urgent need within the global swine production market.
Our therapeutics and vaccines can be used to prevent or mitigate the effects of outbreaks of SIV in the swine populations, decrease the use of antibiotics needed to treat secondary infections, overcome issues associated with maternal antibody interference and fill a need for a broad vaccine as the genetic diversity of SIV increases.
We’re also seeking to leverage the breadth of the HISP technology platform into areas outside SIV market and look to establish partnerships with companies for indications in other species, including humans.